Phase II study of liposomal doxorubicin, docetaxel and trastuzumab in combination with metformin as neoadjuvant therapy for HER2-positive breast cancer.

Ther Adv Med Oncol · 2021 · PMC7876584 · PMID 33613693

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a decreasing trendno p-value reported

During the adjuvant part of treatment, hs-TnT showed a decreasing trend, such that the whole pattern during the neoadjuvant and adjuvant period was better fitted by a quadratic model.

also in 47,180 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.